Barzolvolimab Biosimilar – Anti-CD117 mAb – Research Grade

Barzolvolimab Biosimilar – Anti-CD117 mAb – Research Grade Barzolvolimab Biosimilar – Anti-CD117 mAb – Research Grade Introduction

Barzolvolimab Biosimilar is a monoclonal antibody (mAb) that specifically targets CD117, also known as c-kit, a protein that is overexpressed in certain cancers. This biosimilar is a highly specific and potent therapeutic agent that has shown promising results in preclinical studies.

Structure of Barzolvolimab Biosimilar

Barzolvolimab Biosimilar is a fully humanized IgG1 antibody, meaning it is derived from human genetic material and has a similar structure to the body’s natural antibodies. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa.

Mechanism of Action

Barzolvolimab Biosimilar works by binding to CD117 on the surface of cancer cells and inhibiting its activity. CD117 is a receptor tyrosine kinase that is involved in cell growth and proliferation. When activated, it can lead to uncontrolled cell growth and tumor formation. By blocking the activity of CD117, Barzolvolimab Biosimilar can slow down or even stop the growth of cancer cells.

Applications of Barzolvolimab Biosimilar

Barzolvolimab Biosimilar is primarily being developed as a therapeutic agent for the treatment of various cancers. It has shown promising results in preclinical studies for the treatment of solid tumors, including breast, lung, and ovarian cancers, as well as hematological malignancies such as leukemia and lymphoma.

Advantages of Barzolvolimab Biosimilar

Compared to other anti-CD117 mAbs, Barzolvolimab Biosimilar has several advantages. As a fully humanized antibody, it is less likely to cause an immune response in patients. It also has a longer half-life, meaning it can remain active in the body for a longer period of time, resulting in a longer duration of action. Additionally, Barzolvolimab Biosimilar has demonstrated superior binding affinity and potency compared to other anti-CD117 mAbs.

Research Grade

Barzolvolimab Biosimilar is currently in the research phase and is not yet approved for clinical use. However, it has shown promising results in preclinical studies and is being further evaluated in clinical trials. As a research grade product, it is available for use in laboratory research and development purposes.

Conclusion

Barzolvolimab Biosimilar is a highly specific and potent monoclonal antibody that targets CD117, a protein that is overexpressed in certain cancers. Its unique structure and mechanism of action make it a promising therapeutic agent for the treatment of various cancers. As a research grade product, it is currently being evaluated in clinical trials and has the potential to become a valuable addition to the treatment options for cancer patients.

Keywords

Barzolvolimab Biosimilar, Anti-CD117 mAb, monoclonal antibody, CD117, c-kit, cancer, therapeutic agent, structure, mechanism of action, applications, advantages, research grade.